Born from MIT's groundbreaking research and the collective ambition of industry veterans and technology innovators, Travera developed the RapidSelection™ test to enable truly personalized therapy selection through revolutionary cellular biometrics.
Since 2018, multiple clinical studies at prominent academic medical institutions in the United States gathered clinical evidence for the accuracy of our rapid therapy selection testing process.
Travera's CLIA-certified Laboratory Developed Tests (LDTs) currently span virtually all cancer drugs (immunotherapies, targeted inhibitors, cytotoxics, etc.).
Visit travera.com
Contact Us
